Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore
Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Agilent Technologies (NYSE:A | A Price Prediction) heads into a pivotal earnings setup for retirement-oriented portfolios, with a company-confirmed Q3 2026 report after the close on Aug. 26 arriving on top of a raised guide, expanding margins, and a fresh product cycle that management already said Ignite pulled forward by a full quarter. Every operating lever is pointing the same direction, leaving little room for a coin-flip outcome.
Beat-and-Raise Momentum Is Already Compounding
Agilent walked out of Q2 with revenue of $1.835 billion, up 10.01% year over year, non-GAAP EPS of $1.49 versus a $1.4083 estimate (a 5.8% surprise), and non-GAAP operating margin of 26.4%, up 130 basis points. Net income jumped 57.67%. Management then raised the full year to $7.39B–$7.49 billion in revenue and $6 to$6.10 in EPS. The Q3 guide of $1.83 billion to $1.85 billion in revenue and $1.48–$1.50 EPS is the number to clear, and the last beat produced a 16.87 day-of-change.
Catalyst Stack: 9500 ICP-MS, Replacement Cycle, Ignite
The 9500 triple quad ICP-MS launch was expedited by a full quarter via Ignite, and Agilent has now printed a book-to-bill above one for nine consecutive quarters. Instrument revenue grew high single digits with LC, LC-MS, and GC in the low double digits. Pricing delivered roughly 200 basis points in Q2, double the original full-year goal. This is a durable margin story into a live replacement cycle.
Valuation and the Head-to-Head
Agilent trades at a forward P/E of 22 with an analyst target of $160.11 and 17 Buy or Strong Buy ratings against zero Sell ratings. Compare that to Waters Corporation (NYSE:WAT), which is still digesting the BD Biosciences deal. Waters posted a Q2 net loss of $136 million against $232 million of intangible amortization and $155 million of inventory step-up charges, with organic constant-currency growth of 9%. Against Thermo Fisher Scientific (NYSE:TMO), Agilent’s 26.4% operating margin beats Thermo’s 22.8% adjusted operating margin, and Agilent grew reported revenue faster in Q2 (10.01% versus Thermo’s 10.49% with far less acquisition help). Cleaner P&L, better margin, same growth.
Only Real Risk, Dismissed
Bears point to the Q1 FY2026 miss (EPS $1.36 versus $1.3683), but management tied it to a U.S. snowstorm in the final week and still raised full-year guidance. Q2 answered with a clean beat and another raise. The stock is now up more than 22% in one month and 33.5% over the past year, and it still sits below the $160.11 analyst target.
Keep an eye on the stock into the August 26 close.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
